Singapore Clinical Trial: CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Singapore, May 20 -- The Health Sciences Authority received information related to the study titled 'CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety... Read More

Singapore Clinical Trial: CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Singapore, May 20 -- The Health Sciences Authority received information related to the study titled 'CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety... Read More

Clinical Trial: Evaluation of Sensitivity and Color Change of Different Protocols of In-office Dental Bleaching

U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07597044) titled 'Evaluation of Sensitivity and Color Change of Different Protocols of In-office Dental Bleach... Read More

Singapore Clinical Trial: A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium-177 (177Lu) Rosopatamab Tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with Prostate-Specific Membrane Antigen (PSMA) Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Receptor Pathway Inhibitor (ARPI) Treatment

Singapore, May 20 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lut... Read More

Singapore Clinical Trial: CO45042: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib Plus Pembrolizumab Versus Pembrolizumab And Pemetrexed And Carboplatin or Cisplatin in Patients with Previously Untreated, KRAS G12C-Mutated, Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Singapore, May 20 -- The Health Sciences Authority received information related to the study titled 'CO45042: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib ... Read More

Clinical Trial: Perception, Risk Behaviour, and Attitudes Related to Non-communicable Disease

U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07597434) titled 'Perception, Risk Behaviour, and Attitudes Related to Non-communicable Disease' on May 13. B... Read More

Singapore Clinical Trial: A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Singapore, May 20 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durv... Read More

Singapore Clinical Trial: TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer

Singapore, May 20 -- The Health Sciences Authority received information related to the study titled 'TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-labe... Read More

Singapore Clinical Trial: A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

Singapore, May 20 -- The Health Sciences Authority received information related to the study titled 'A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety... Read More

Clinical Trial: AI-Assisted Implant Planning Using CBCT Data

U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07597785) titled 'AI-Assisted Implant Planning Using CBCT Data' on May 08. Brief Summary: This retrospective ... Read More

• ««
• «
• 4392
• 4393
• 4394
• 4395
• 4396
• 4397
• 4398
• 4399
• 4400
• 4401
• »
• »»